Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Lantheus (LNTH)

Lantheus to buy Evergreen Theragnostics for $250 million upfront plus milestones

Neutral Impact 4 of 5 m&a Written later

Lantheus agreed to acquire Evergreen Theragnostics, a clinical-stage radiopharmaceutical company with a contract manufacturing business, for a $250 million cash upfront payment plus up to $752.5 million in milestone payments. The company also reaffirmed its full-year 2024 revenue and adjusted EPS guidance, and the deal is expected to close in the second half of 2025, subject to regulatory clearances.

Key points

  • Upfront cash payment of $250 million at closing, plus up to $752.5 million in milestone payments tied to OCTEVY and Evergreen's pipeline
  • Reaffirmed FY 2024 revenue guidance of $1.51 billion to $1.52 billion and adjusted fully diluted EPS guidance of $6.65 to $6.70
  • Closing expected in the second half of 2025; reverse termination fee of $10 million payable to Evergreen in certain regulatory-failure cases
  • Investor presentation says the deal is low single digit percent dilutive to Lantheus stand-alone EPS in the near term

The filing

CompanyLantheus (LNTH)
Form8-K, current report
Filed with the SECJan 28, 2025, 6:23 AM ET
Accession number0001193125-25-013841

Items reported: 1.01 Material Definitive Agreement2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 28, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.